Navigation Links
Exelixis Announces Third Quarter 2007 Financial Results and Business Update
Date:11/5/2007

SOUTH SAN FRANCISCO, Calif., Nov. 5 /PRNewswire-FirstCall/ -- Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the third quarter ended September 30, 2007.

Revenues for the quarter ended September 30, 2007 were $26.8 million, compared to $23.5 million for the comparable period in 2006. The increase in revenues from 2006 to 2007 was primarily due to revenue recognition associated with new collaboration agreements with Bristol-Myers Squibb Company for various oncology programs and Genentech, Inc. for the XL518 program. The increase was partially offset by the completion of revenue recognition related to the upfront payment associated with the collaboration agreement with Daiichi Sankyo Company Limited for our mineralocorticoid receptor (MR) program.

Research and development expenses for the quarter ended September 30, 2007 were $58.6 million, compared to $46.0 million for the comparable period in 2006. The increase from 2006 to 2007 was primarily due to increased development expenses associated with the continued expansion of our clinical trial activity and the advancement of our compounds through preclinical development.

General and administrative expenses for the quarter ended September 30, 2007 were $10.8 million, compared to $8.8 million for the comparable period in 2006. The increase from 2006 to 2007 was primarily due to personnel expenses and stock-based compensation expense to support our expanding operations.

Net loss for the quarter ended September 30, 2007 was $13.7 million, or $0.14 per share, compared to $25.2 million, or $0.30 per share, for the comparable period in 2006. The decrease in the net loss from 2006 to 2007 was primarily due to an $18.8 million gain on th
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Dow AgroSciences and Exelixis Plant Sciences Announce Major Research Collaboration, Asset Purchase to Advance Gene Discovery and Validation
2. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
3. Exelixis Announces Closing of Public Offering of Common Stock
4. Exelixis Submits XL880 Diligence Report to GlaxoSmithKline
5. Exelixis Announces November 5 Webcast of its 2007 Third Quarter Financial Results Conference Call
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
8. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
9. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
10. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
11. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... Michigan (PRWEB) , ... September 03, 2015 , ... ... to release its non-invasive hydration monitoring wearable early 2016. , The device, ... level using proprietary optical and electrical sensing technology. These sensors track trending ...
(Date:9/2/2015)... Sept. 2, 2015 Research and ... addition of Jain PharmaBiotech,s new report ... their offering. An increasing ... biotechnology industries is anticipated. Nanotechnology will be ... - from formulations for optimal delivery to ...
(Date:9/2/2015)... 2015 Research and ... of Jain PharmaBiotech,s new report "Biochips and ... their offering. This report is an ... applications. The report starts with a description of ... Technologies include array comparative genomic hybridization (CGH), copy ...
(Date:9/2/2015)... Research and Markets ( ... new report "Gene Therapy - Technologies, Markets and ... for gene therapy are difficult to estimate as there ... is marketed in China since ... 2014-2024. The estimates are based on epidemiology of diseases ...
Breaking Biology Technology:Technology Startup Halo Wearables to Unveil Non-Invasive Hydration Monitoring Device Early 2016 2Global Nanobiotechnology Applications, Markets and Companies Report 2015-2024 2Global Nanobiotechnology Applications, Markets and Companies Report 2015-2024 3Global Biochips and Microarrays Technologies, Markets and Companies Report 2015 with Market Size in 2014 and Projected Value for the Years 2019 and 2024 2Global Gene Therapy Market Study 2015-2024 - Technologies, Markets and Companies Analysis 2
... Corporation announced today the,commercial release of its Extended ... This technology breaks through classical depth of field,limitations ... of the ImageStream system and enabling new applications,including ... EDF option can be installed at time of ...
... (Nasdaq: MATK ) announced that it intends to ... on June 4, 2008, at approximately 4:00,p.m. Eastern Time ... will,conduct a conference call to discuss the results of ... parties may listen to the call,live via webcast by ...
... N.J., May 22 In an address to,shareholders ... Inc.,(NYSE: MHS ) Chairman and CEO David ... key strategic drivers designed to deliver strong,continuing earnings ... generics, mail-order and specialty pharmacy to retaining and ...
Cached Biology Technology:Amnis Announces Release of Its Extended Depth of Field Option for The ImageStream(R) System 2Medco CEO to Shareholders: Delivering Results, Driving Shareholder Value 2Medco CEO to Shareholders: Delivering Results, Driving Shareholder Value 3Medco CEO to Shareholders: Delivering Results, Driving Shareholder Value 4
(Date:8/31/2015)... 31, 2015 Growing need for ... government digitization projects to drive India ... TechSci Research report, " India Biometrics Market Forecast & Opportunities, ... is projected to grow at a CAGR of over 35% ... on account of extensive use of biometric technology in the ...
(Date:8/24/2015)... 24, 2015 The consulting company Frost ... biometrics manufacturer DERMALOG and its customized solutions and products for ... Company of the Year Award". DERMALOG is particularly successful with ...   -Cross reference: Picture is available at AP ... On Thursday evening, in South Africa,s ...
(Date:8/19/2015)...  VOXX International Corporation (Nasdaq: VOXX ) ... Definitive Agreement to purchase the assets, inclusive of ... EyeLock through an acquiring entity.  Upon consummation of ... in the acquiring entity. The closing of the ...  Expanding on its existing supply chain and distribution ...
Breaking Biology News(10 mins):India Biometrics Market to Grow at Over 35% Through 2020, Says TechSci Research 2India Biometrics Market to Grow at Over 35% Through 2020, Says TechSci Research 3Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 2Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 2VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 4VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 5
... following highlights summarize research papers that have been recently ... Journal of Geophysical ,Research-Solid Earth (JGR-B), and ... , 1. Active faults newly identified in Pacific Northwest ... Seattle and south of Vancouver, ,British Columbia, around the ...
... University of Minnesota invention could help make storage of ... invention was licensed to SustainX, a leading global developer ... compressed air methods to store large amounts of energy ... sources, like wind and solar, are unpredictable. The wind ...
... AURORA, Colo. (April 16, 2012) Researchers at the ... lack of a specific gene interrupts neural tube closure, a ... tube is the beginning of the brain and spinal cord," ... pediatrics at the CU School of Medicine. "A defect in ...
Cached Biology News:AGU journal highlights for March 29, 2012 2AGU journal highlights for March 29, 2012 3AGU journal highlights for March 29, 2012 4AGU journal highlights for March 29, 2012 5AGU journal highlights for March 29, 2012 6AGU journal highlights for March 29, 2012 7AGU journal highlights for March 29, 2012 8
DNA Purification...
Porcine Serum Available Anticoagulants: N-02: Citrate N-04: Heparin (Na) N-06: K2EDTA N-08: Potassium Oxalate N-10: EDTA (Na) N-03: Alsevers N-05: ACD N-07: CPD N-09: K3EDTA N-11...
Recombinant Viral CCI/Fc Chimera, CF...
... • Guinea Pig serum is collected from ... N-02: Citrate N-04: Heparin ... Potassium Oxalate N-10: EDTA (Na) ... N-07: CPD N-09: K3EDTA ...
Biology Products: